ApDC

Aptamer Drug Conjugates: A Novel Targeted Delivery Platform for Oncology

...

ApDCs

Targeted therapy modality in which aptamers replace mAbs in drug conjugates

Have target specificity and affinity on par with mAbs

Can be selected for inhibitory, stimulatory, or no biological activity

Support receptor-mediated internalization

Different aptamers may be joined to form bi-specific therapeutic agents

ApDC payload can be tailored to suit therapeutic strategy:

Chemotherapeutic toxin
Immunostimulant
RNAi, ASO, miRNA, etc.

ApDCs offer significant CMC advantages over ADC

CMC Advantages of ApDC vs. ADC

Immuno-stimulatory oliogonucleotides (e.g., CpG sequences) can be directly synthesized as chimeric extension of targeting aptamer sequence

...

Streamlined manufacturing/analytical chemistry approach

...

Lower COGS

...

Shortened CMC development lead times

Chemotherapeutic toxin payload conjugation chemistry is simplified

...

Site-specific conjugation using NHS-, thiol or Click chemistry

...

Constant 1:1 stoichiometry of targeting and payload moieties

...

On equimolar basis, more payload for ApDC than ADC

MW of aptamer is between 10,000 to 15,000

Contact

© 2021 Guardian Therapeutics. All rights reserved.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com